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Objective: To determine the gender and age-based disparities in side effects among healthcare workers in 
response to COVID-19 (Sinopharm) vaccination  
Materials and Methods: A total of 216 healthcare workers were vaccinated against COVID-19 by administering 
Sinopharm vaccine during February and March 2021 at the Infectious Diseases Department of Holy Family 
Hospital, Rawalpindi. They were enrolled in the study through consecutive sampling. Data for this cross-sectional 
descriptive study was gathered pertinent to age, gender, and side effects of Sinopharm vaccination. The 
information regarding vaccination side effects was inquired through telephonic calls. Statistical analysis of data 
was done by SPSS version 25.0. Gender-based differences in post-vaccination side effects with a first and second 
dose of vaccine were statistically confirmed by the application of the chi-square test. P-value < 0.05 was taken as 
significant.  
Results: Mean age of healthcare workers in our study was 35.7 ± 9.5 years. Most (54.6%) of them were females 
and 79.2% of health professionals were 21-40 years old. Side effects after the first dose of Sinopharm vaccine were 
experienced by 46.3% males and 42.4% females. About 45.2% and 42.3% of males and females respectively 
overlooked the second jab adversity. A greater proportion (43.6%) complained of vaccine-related side effects after 
the second dose than 37.5% of subjects who noted side effects after the first dose of vaccine. Body aches, injection 
site pain, headache, and fever were established as the commonest post-vaccination side effects. Gender-based 
variations between post-vaccination side effects were statistically insignificant both with the first dose (P>0.1) and 
second dose (P>0.2) of the Sinopharm vaccine. 
Conclusion: Side effects resulting from the Sinopharm vaccine among our healthcare personnel were minimal. 
Fortunately, none of them complained of serious aftereffects. Despite the COVID vaccination, our healthcare 
workers should strictly adhere to COVID SOPs amidst pandemics in order to avoid catastrophe in the future.  
Keywords: COVID-19, Sinopharm vaccine, side effects, body aches, injection site pain, healthcare professionals. 
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Introduction 
 
COVID-19 pandemic has led to the confrontation with 
gigantic challenges of disrupted social, economic, 
educational, and health facets across the globe. This 
state of affairs has stimulated our policymakers to 
strive for the survival of humanity by sustainable 
development.1 Diverse research funds are being 
granted worldwide in wake of COVID-19 to arrest the 
spread of this calamity by exploring the culprit and 
evolving the way out for its mitigation.2 
The ending of COVID infection into fatal 
complications and mortalities prompted the scientists 
universally to initiate the production of vaccines.3 
GAVI & WHO in collaboration with other agencies 
intended to control the spread of coronavirus infection 
by expediting the development of efficacious vaccines. 
The need-based issuance and availability of vaccines 
were also ensured across the globe apart from their 
development.4 The National Command Operation 
Center (NCOC) Government of Pakistan established a 
portal to facilitate frontline healthcare workers and 
senior citizens in getting vaccinated against COVID-19 
through the development of an apt registration system 
and provision of guidelines for vaccination.5  
The COVID-19 vaccines produced worldwide have 
undergone numerous phases of a clinical trial before 
getting safety verification.6 Undoubtedly, the 
vaccination against COVID-19 has been proven to 
substantially reduce the likelihood of infection 
transmission and hence the escalation of cases.7 But 
side effects might be obvious following COVID 
vaccines due to the production of antibodies in 
response to inflammation.8 The alarming lift in a 
number of COVID cases reported during the third 
wave is attributed to the contagiousness and fatal of 
the British variant. The government of Pakistan is 
battling the third surge of COVID-19 by means of 
numerous healthcare weapons in order to limit the 
resultant fatalities. Non-adherence to the COVID SOPs 
is proven to be the culprit. The only optimism in this 
distressed situation appears to be the COVID 
vaccination national campaign carrying out across the 
country with prioritization of the most vulnerable 
population.9  
About 95% of healthcare workers of Pakistan got 
vaccinated themselves against COVID-19 without the 
fear of its side effects. The event they did not bother 
about limited evidence on vaccine effectiveness.10 
About 224,000 healthcare personnel of Pakistan are 
known to receive two doses of the Sinopharm vaccine 
safely. Efforts for vaccination of maximum healthcare 
providers are again promulgated by providing 
opportunities for re-registration of missed personnel11. 
Mild side effects resultant of vaccination should be 
catered to by symptomatic treatment as they are an 
indication of the body’s immune response.12 
The current study is planned to outlook the side effects 
experienced by our healthcare professionals following 
the Sinopharm vaccine. Their vaccination is meant to 
safeguard them against fatal coronavirus infection as a 
majority of COVID confirmed and suspected cases are 
visiting tertiary healthcare facilities. The identification 
of ensuing vaccine side effects may facilitate in 
mitigation of unfavorable effects for further vaccinated 
staff by relatable timely intervention. 
 
Materials and Methods 
 
Cross-sectional descriptive research was carried out 
among 216 healthcare workers who got vaccinated 
with Sinopharm vaccine during February and March 
2021 in Infectious Diseases department of Holy Family 
Hospital Rawalpindi after getting confirmation SMS 
through NCOC Government of Pakistan registration 
platform5. Health care professionals who received 
either one or two jabs of Sinopharm vaccine at Holy 
Family Hospital were enrolled in this study through 
consecutive sampling. Data were collected regarding 
the age and gender of our healthcare staff along with 
their post-vaccination side effects through telephonic 
calls. However, the past medical history of the study 
participants was not inquired. Data analysis was done 
by using SPSS version 25.0. Percentages and 
frequencies for all variables were computed. Gender-
based differences in post-vaccination side effects 
experienced after the first and 2nd dose of Sinopharm 
vaccine were statistically verified by chi-square test. P-




Of the total 216 healthcare professionals vaccinated 
against COVID-19 by administering Sinopharm 
vaccine, 118 (54.6%) were females while 98 (45.4%) 
were males. The mean age of our study participants 
was 35.7 ± 9.5 years. The majority of our health care 
professionals who were vaccinated against COVID-19 
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Table 1: Age distribution of Vaccine recipients at 





No. of vaccine 
recipients 
Males Females 
1. 11-20  02 0 02 
2. 21-30  84 33 51 
3. 31-40  87 41 46 
4. 41-50  24 13 11 
5. 51-60  17 09 08 
6. 61-70  02 02 0 
Total  216 98 118 
 
Adverse effects experienced after 2nd dose of vaccine 
were comparatively more than those experienced after 
the first dose. However, gender-based differences in 
side effects experienced by healthcare professionals 
after the first and second dose of the Sinopharm 
vaccine were determined to be statistically 
insignificant as depicted below in Table 2. 
 
Table 2: Gender-based differences in side effects 
experienced after 1st and 2nd dose of Sinopharm 
vaccine 
Gender 
(n = 216) 
Side effects experienced 
after 1st dose of vaccine 
Total 
Yes No 
Males 31(46.3%) 67 (53.7%) 98 
Females 50 (42.4%) 68 (57.6%) 118 
Total 81 (37.5%) 135 (62.5%) 216 
X2 = 2.63                   P > 0.1 
Gender  
(n = 94) 
Side effects experienced 
after 2nd  dose of vaccine 
Total  
Yes No 
Males 19 (45.2%) 23 (54.8%) 42 
Females 22 (42.3%) 30 (57.7%) 52 
Total 41 (43.6%) 53 (56.4%) 94 
X2 = 0.09            P > 0.2 
 
Table 3: Age-based differences in adverse effects 
experienced with 1st and 2nd dose of Sinopharm 
vaccine 
Age groups Adverse effects overlooked with 
Sinopharm vaccine 
1st dose 
(n = 216) 
2nd dose 
(n = 94) 
11-20 years 0 0 
21-30 years 35 17 
31-40 years 32 14 
41-50 years 7 6 
51-60 years 7 3 
61-70 years 0 1 
Total  81 (37.5%) 41 (43.6%) 
About 62.5% and 55.3% of healthcare workers did not 
experience post-vaccination side effects after the first 
and second dose of Sinopaharm vaccine respectively. 
However, mild resultant symptoms experienced are 
shown below in Figure 1.  
 
 
Figure 1: COVID vaccine-related side effects among 
healthcare personnel 




People across the globe have ensured the best possible 
means to limit the spread of coronavirus infection but 
lack of immunity to this virus still makes them 
vulnerable to this infection.13 The induction of immune 
response is of prime concern predominantly among 
our healthcare personnel and elders14 and hence 
protection against SARS-CoV-2 by means of 
vaccination is globally prioritized.15 This issue 
triggered worldwide efforts towards the development 
of a vaccine in wake of the COVID-19 pandemic.  
Of the total 216 healthcare professionals vaccinated 
against COVID-19 by administering Sinopharm 
vaccine at Holy Family Hospital Rawalpindi, minimal 
side effects were experienced by approximately 81 
recipients after the first dose of vaccine. The second 
dose was administered to only 93 healthcare workers 
and among them, 41 complained of some adverse 
effects. The Sinopharm vaccine also labeled as Vero 
contains inactivated virus. This vaccine is being 
administered in a Phase-III trial that was conducted in 
10 countries across the world including Pakistan. The 
resulting adverse effects following immunization are 
known to subside gradually and their occurrence is an 
indication of a functional immune system.16  
Fortunately, 62.5% of our Sinophram vaccine first jab’s 
recipients did not experience any side effects. 
However among the rest of the 37.5% having adverse 
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effects with the first dose of vaccine, most (22) 
complained of body aches while 21, 20, and 18 
suffered from headache, fever, and injection site pain 
respectively. On the other hand, among 91 healthcare 
personnel receiving the 2nd dose of vaccine about 
43.6% experienced unfavourable symptoms. The 
majority (24.4%) complained of dermal rash while 22% 
and 19.5% had injection site pain and fever 
respectively. Although preliminary overview about 
Sinopharm vaccine confirms its safety for human 
beings and ensures minimal resultant side effects 
sufficient data pertinent to side effects experienced 
altogether with Sinopharm vaccine is not available as 
numerous vaccines including Pfizer, Moderna, 
CoronaVac, and Sinopharm vaccines with provisional 
efficacy are sanctioned for administration across the 
globe in order to protect human beings against the 
fatal virus.17,18 Likewise, in the current study, the 
majority of the participants undergoing phases 1 and 2 
of Randomized Controlled Trial with aforementioned 
sanctioned vaccines overlooked vaccine-associated 
adversity after 2nd dose. Injection site pain, erythema, 
fever, headache, and myalgia were experienced by 
vaccine recipients up to 7 days after 2nd dose 
administration.19 Similarly approximately 50% of 
Pfizer vaccine recipients experienced injection site 
pain, headache, or fatigue after 2nd dose 
administration.20 It is essential to counsel layman 
vaccine recipients about the vaccine-related proposed 
side effects in order to ensure symptomatic 
management rationally and avoidance of nuisance. 
This approach will facilitate a great deal to reduce the 
additional burden on healthcare facilities amidst the 
COVID pandemic.  
The results of the present study illustrated that 
mainstream (46.3%) COVID vaccine first jab recipients 
complaining of post-vaccination side effects were 
males. Even after the second dose, adverse effects in 
high magnitude (45.2%) were reported among our 
male healthcare professionals. Contrary to our 
research, COVID vaccine-related side effects explored 
by Yale School of Medicine were identified in high 
propensity (72%) among females.21 A similar study by 
Folegatti A, et al concluded that only mild and 
moderate post-vaccination adverse effects were 
determined.22 Centre for Disease Control and 
Prevention (CDC) reported that more females 
experienced COVID vaccine-associated side effects 
than males.23 In addition, fever was reported to be the 
commonest side effect, particularly among females.24 
According to experts, the intense COVID vaccine-
related side effects among females are attributed to 
their strong immune response and this might be 
accounted to gender-based hormonal differences.25 
These gender-based discrimination in adversity 
following COVID vaccination can better be 
streamlined by enrolling a large study population in 
this regard.  
In the current study, as most of our vaccinated subjects 
were youngsters with only little study population 
older than 60 years, so an almost equal proportion of 
youth and elders was observed to have side effects. On 
the other hand, more young adults internationally 
seemed to have adverse effects with the COVID 
vaccine.26 A second dose of vaccine in our study was 
received by only 94 healthcare workers, this age-based 
disparity can better be discovered by securing data 
pertinent to side effects from the majority of our 
vaccinated populates including other than those of 
healthcare personnel.  
Almost all COVID vaccines are determined to have 
two doses; the first dose is meant to elicit immune 
response while the second one is intended to boost 
immunity. Almost similar side effects of all COVID 
vaccines (Russian, American, Chinese or British) are 
reported with most frequently established to be flu-
like symptoms and injection site allergies.27 These 
variations in post-vaccination side effects however can 
best possibly be unmasked by the conduction of more 




The Sinopharm vaccine was determined to be quite 
favorable for our healthcare workers as the minority of 
the workers experienced its side effects. However, 
precautionary measures against COVID-19 should still 
be observed religiously in order to keep safe and 
healthy during pandemic waves. 
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